# A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00821249** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 55 (actual)

## Conditions studied

- Multiple Myeloma
- Plasma Cell Leukemia

## Interventions

- **DRUG:** ARRY-520, KSP(Eg5) inhibitor; intravenous
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
- **DRUG:** Dexamethasone, steroid; oral

## Key facts

- **NCT ID:** NCT00821249
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-03-16
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00821249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00821249, "A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00821249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*